Phathom Pharmaceuticals
CompanyUnited States
Phathom Pharmaceuticals develops 2 assets, the furthest approved (vonoprazan in heartburn). Mostly small molecule acting on ATP4A and ATP4B; based in the United States.
- 2
- Assets
- Furthest stage
- Approved
- 14
- Trials
- 12
- Signals
Pipeline
2Blocks gastric proton pumps competitively with potassium to suppress stomach acid secretion.
Approved, Small molecule, ATP4A, ATP4B, heartburn, Erosive Esophagitis
Combines vonoprazan-mediated gastric acid suppression with amoxicillin and clarithromycin to eradicate Helicobacter pylori.
Approved, Small molecule, Helicobacter pylori infection, gastric cancer (Phase 3)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials16
- Deals4
- People20
- Signals15
- Similar companies6